ENTITY
Ascletis Pharma

Ascletis Pharma (1672 HK)

112
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
more
Exchange Announcement • 14 Oct 2026 18:29

Next Day Disclosure Return

Exchange Announcement • 13 Oct 2026 17:27

Next Day Disclosure Return

Exchange Announcement • 12 Oct 2026 18:53

Next Day Disclosure Return

Exchange Announcement • 02 Oct 2026 16:50

Voluntary Announcement - Ascletis' Asc36_35fdc Demonstrated Potential For Once-Monthly To Once-Quarterly Dosing And Robust Weight-Loss In Preclinical Studies Presented At Easd 2026

Exchange Announcement • 29 Sep 2026 17:01

Interim Report 2026

x